IP Library › Granted Patent US 8,147,852
Granted Patent B2
US 8,147,852 · App. 12/108,262 · Granted Apr 3, 2012

Modified azole compounds as antifungal and antibacterial agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,147,852
App. No.
12/108,262
Granted
Apr 3, 2012
Kind
B2
Abstract

The present invention relates to the compounds of formula (I), their preparation and use as antifungal and/or antibacterial agents. where the values for R 1 , R 2 , R 3 , R 4 , R 5 and A are as defined herein.

Claims (27)

1. A method of treating a human suffering from candidiasis, comprising topically administering to the human an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition is in the form of an ointment and comprises a compound of the formula

2. The method according to claim 1 , wherein the pharmaceutical composition further comprises miconazole nitrate.

3. The method according to claim 1 , wherein the pharmaceutical composition further comprises 2,6-di-tert-butyl-4-methylphenol.

4. The method according to claim 1 , wherein the pharmaceutical composition further comprises zinc oxide.

5. The method according to claim 1 , wherein the pharmaceutical composition further comprises a petrolatum.

6. The method according to claim 5 , wherein the petrolatum is white petrolatum.

7. The method according to claim 1 , wherein the pharmaceutical composition further comprises trihydroxystearin.

8. The method according to claim 1 , wherein the candidiasis is caused by a Candida spp, selected from the group consisting of Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsiliosis, Candida guilliermondi, Candida lusitaniae and Candida krusei.

9. The method according to claim 8 , wherein the Candida spp, is Candida albicans.

10. The method according to claim 1 , wherein the human is also suffering from diaper rash.

11. A method of treating a human suffering from candidiasis, comprising topically administering to the human an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition is in the form of an ointment and comprises a compound of the formula

miconazole nitrate;

zinc oxide;

white petrolatum; and

trihydroxystearin.

12. The method according to claim 11 , wherein the candidiasis is caused by a Candida spp, selected from the group consisting of Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsiliosis, Candida guilliermondi, Candida lusitaniae and Candida krusei.

13. The method according to claim 12 , wherein the Candida spp, is Candida albicans.

14. The method according to claim 11 , wherein the human is also suffering from diaper rash.

15. A method of treating a human suffering from candidiasis, comprising topically administering to the human an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition is in the form of an ointment and consists of a compound of the formula

miconazole nitrate;

zinc oxide;

white petrolatum;

trihydroxystearin; and

optionally a fragrance.

16. The method according to claim 15 , wherein the candidiasis is caused by a Candida spp, selected from the group consisting of Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsiliosis, Candida Candida Iusitaniae and Candida krusei.

17. The method according to claim 16 , wherein the Candida spp, is Candida albicans.

18. The method according to claim 15 , wherein the human is also suffering from diaper rash.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2016
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR IN INTEREST TO GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: RENAISSANCE SSP HOLDINGS, INC.; RENAISSANCE PHARMA (U.S.) HOLDINGS, INC.; RENAISSANCE PHARMA, INC.; PRESTIUM PHARMA, INC.; DPT LAKEWOOD, LLC; DPT LABORATORIES, LTD.; RENAISSANCE ACQUISITION HOLDINGS, LLC; RENAISSANCE DPT PARTNER SUB, LLC; DELCOR ASSET CORPORATION; DENCO ASSET, LLC
Reel/Frame 038930/0777 →
SECURITY INTEREST Recorded Nov 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037111/0389 →
SECURITY AGREEMENT Recorded Aug 12, 2013
From: DELCOR ASSET CORPORATION
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 031003/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2013
From: STIEFEL LABORATORIES, INC.
To: DELCOR ASSET CORPORATION
Reel/Frame 030531/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2012
From: BARRIER THERAPEUTICS, INC
To: STEIFEL LABORATORIES INC
Reel/Frame 028232/0370 →